KODKodiak Sciences Inc.
$32.34+207% 1Y
$32.34
$11.6052 weeks$99.91
Latest close: a new 52-week highOct 9, 2026what changed →
KOD in its own filings
KOD's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
132
Events found in the filings · across 418 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 28, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 13, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Delisting notice / listing-rule failurehistorical
- 2019-10-10
- SEC comment-letter activity15 occurrences
- 2023-05-31
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, Kodiak Sciences Inc. (the “Company”) issued a press release announcing that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Company’s Phase 3 DAYBREAK study in patients with wet age-related macular degeneration.Other event · Form 8-K
- Aug 13, 2026Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results.Earnings release · press release
- May 7, 2026Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results.Earnings release · press release
- Mar 31, 2026Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Mar 27, 2026On March 26, 2026, Kodiak Sciences Inc. (the “Company”) issued a press release announcing positive topline results in GLOW2, the Company’s second Phase 3 study in diabetic retinopathy, demonstrating superiority of Zenkuda ™ (tarcocimab tedromer) over sham.Other event · Form 8-K
- Dec 18, 2025On December 16, 2025, Kodiak Sciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C. and UBS Securities LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”) …Other event · Form 8-K
- Nov 13, 2025Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks